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ABSTRACT  
Colon targeted tablets were prepared in two steps. Initially core tablets were prepared and then the tablets were coated by u sing different pH 
dependent polymers. Ethyl cellulose, Eudragit L100 and S100 were used as coating polymers. FT-IR studies were carried out to find out the 
possible interaction between the selected drugs and polymer. FT-IR studies revealed that  there  was  no  interaction between the selected drug 
and excipients. The pre-compression blend of all formulations was subjected to various flow property tests and all the formulations passed the 
tests. The tablets were coated by using polymers and the coated tablets were subjected to various evaluation techniques. The tablets passed all 
the tests. Among all the formulations F3 formulation was found to be optimized as it was retarded the drug release up to 12 hours and showed 
maximum of 97.57% drug release. It followed zero order kinetics mechanism. The ideal formulation was subjected to stability studies at 
40°C/75%RH. The stability studies indicated that the formulation was stable and retained its pharmaceutical properties at 40°C/75%RH over 
a period of 1 month. 
Keywords: Colon target, Ethyl cellulose, Eudragit L100 and S100, pH dependent polymers.  
 
Article Info: Received 13 Dec 2019;     Review Completed 28 Jan 2020;     Accepted 03 Feb 2020;     Available online 15 March 2020 
Cite this article as: 
Naga Durga DH, Sowjanya TL, Pavani T, Duppala L, Formulation development and in-vitro evaluation of Molsidomine 
matrix tablets for colon specific release, Journal of Drug Delivery and Therapeutics. 2020; 10(2):59-68  
http://dx.doi.org/10.22270/jddt.v10i2.3900                                                                                    
*Address for Correspondence:  
Dr. D. Hema Naga Durga, Division of Pharmaceutics, AVANTHI Institute of Pharmaceutical Sciences, Cherukupally (V), Bhogapuram (M), 




The oral route is considered to be most convenient for 
administration of drugs to patients. Oral administration of 
conventional dosage forms normally dissolves in the 
stomach fluid or intestinal fluid and gets absorbed from 
these regions of the gastrointestinal tract (GIT) depending 
upon the physicochemical properties of the drug. 
Molsidomine is a nitrovasodilator that causes vasodilation 
(widening of blood vessels) by donation of nitric oxide (NO), 
and is mostly used for the treatment and prevention of 
angina pectoris. Oral absorption of Molsidomine is found to 
be 95.5% ±4.5 and volume of distribution is found to be 98 
litre1-5. 
The aim of the present research work was to develop 
sustained release matrix formulation of Molsidomine 
targeted to colon by using various polymers and in-vitro 
drug release study. The objectives of the study were to 
prepare Molsidomine as a colon targeted tablet. 
Molsidomine matrix tablets containing several retarding 
agents separately were used in order to extend the release of 
drug over the desired period of time and also to evaluate 
these formulations by in-vitro methods and to select the best 
formulation among them. The formulations for 
physicochemical properties were evaluated and also 
interpret kinetic studies6-11. 
MATERIAL AND METHODS 
Materials  
Molsidomine was gifted by M/s. Natco LABS, Ethyl Cellulose 
was purchased from M/s. Signet Chemical Corporation, 
Mumbai, India. Eudragit L-100, Eudragit S-100, Magnesium 
stearate, Micro crystalline cellulose, Talc were purchased 
from M/s. Merck Specialities Pvt Ltd, Mumbai, India. 
Methods 
Analytical method development: 
Determination of absorption maxima: 
A solution containing a concentration of 10 µg/ ml was 
prepared in 0.1N HCl, 7.4 pH & phosphate buffer of 6.8 pH 
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respectively, UV spectrum was taken using Double beam 
UV/VIS spectrophotometer. The solution was scanned in the 
range of 200-400nm. 
Preparation of calibration curve: 
10mg of drug was accurately weighed and dissolved in 10ml 
of 0.1N HCl, 7.4 pH, and 6.8 pH in 10 ml volumetric flask, to 
make (1000 µg/ml) standard stock solution (1). Then 1 ml 
stock solution (1) was taken in another 10 ml volumetric 
flask to make (100 µg/ml) standard stock solution (2), then 
again 1 ml of stock solution (2) was taken in another 10 ml 
volumetric flask and then final concentrations were 
prepared 2, 4, 6, 8, 10, 12, 14, 16, 18, and 20µg/ml with 0.1N 
HCl, 7.4 pH, and 6.8 pH. The absorbance of standard solution 
was determined using UV/ VIS spectrophotometer at 273nm. 
Linearity of standard curve was assessed from the square of 
correlation coefficient (r2) which determined by least-square 
linear regression analysis12,13. 
Drug–Excipient compatibility studies Fourier Transform 
Infrared (FTIR) spectroscopy: 
The physical properties of the physical mixture were 
compared with those of plain drug. Samples was mixed 
thoroughly with 100mg potassium bromide IR powder and 
compacted under vacuum at a pressure of about 12 psi for 3 
minutes. The resultant disc was mounted in a suitable holder 
in Perkin Elmer IR spectrophotometer and the IR spectrum 
was recorded from 3500 cm to 500 cm. The resultant 
spectrum was compared for any spectrum changes. 
Pre-formulation parameters 
The quality of tablet, once formulated by rule, is generally 
dictated by the quality of physicochemical properties of 
blends. There are many formulations and process variables 
involved in mixing and all these can affect the characteristics 
of blends produced. The various characteristics of blends 
tested as per Pharmacopoeia14,15. 
Angle of repose: 
The frictional force in a loose powder can be measured by 
the angle of repose. It is defined as, the maximum angle 
possible between the surface of the pile of the powder and 
the horizontal plane. If more powder is added to the pile, it 
slides down the sides of the pile until the mutual friction of 
the particles producing a surface angle, is in equilibrium with 
the gravitational force. The fixed funnel method was 
employed to measure the angle of repose. A funnel was 
secured with its tip at a given height (h), above a graph paper 
that is placed on a flat horizontal surface16,17. The blend was 
carefully pored through the funnel until the apex of the 
conical pile just touches the tip of the funnel. The radius (r) 
of the base of the conical pile was measured. The angle of 
repose was calculated using the following formula: 
Tan θ = h / r  
Tan θ = Angle of repose 
h = Height of the cone , r = Radius of the cone base 
Table 1: Angle of Repose values (as per USP) 




>40 Very poor 
 
Bulk density: 
Density is defined as weight per unit volume. Bulk density, is 
defined as the mass of the powder divided by the bulk volume 
and is expressed as gm/cm3. The bulk density of a powder 
primarily depends on particle size distribution, particle shape 
and the tendency of particles to adhere together. Bulk 
density is very important in the size of containers needed for 
handling, shipping, and storage of raw material and blend. It 
is also important in size blending equipment. 10 gm 
powder blend was sieved and introduced into a dry 20 ml 
cylinder, without compacting18,19. The powder was carefully 
leveled without compacting and the unsettled apparent 
volume, Vo, was read. 
The bulk density was calculated using the formula: Bulk 
Density = M / Vo 
Where, M = weight of sample 
Vo = apparent volume of powder 
Tapped density: 
After carrying out the procedure as given in the 
measurement of bulk density the cylinder containing the 
sample was tapped using a suitable mechanical tapped 
density tester that provides 100 drops per minute and this 
was repeated until difference between succeeding 
measurement is less than 2 % and then tapped volume, V 
measured, to the nearest graduated unit20,21. The tapped 
density was calculated, in gm per L, using the formula: 
Tap = M / V Where, Tap= Tapped Density 
M = Weight of sample 
V= Tapped volume of powder 
Measures of powder compressibility: 
The Compressibility Index (Carr’s Index) is a measure of the 
propensity of a powder to be compressed. It is determined 
from the bulk and tapped densities. In theory, the less 
compressible a material the more flowable it is. As such, it is 
measures of the relative importance of interparticulate 
interactions. In a free- flowing powder, such interactions are 
generally less significant, and the bulk and tapped densities 
will be closer in value22. 
For poorer flowing materials, there are frequently greater 
interparticle interactions, and a greater difference between 
the bulk and tapped densities will be observed. These 
differences are reflected in the Compressibility Index which 
is calculated using the following formulas: 
Carr’s Index = [(tap - b) / tap] × 100 
Where, b = Bulk Density Tap = Tapped Density 
Table 2: Carr’s index value (as per USP) 
Carr’s index Properties 
5 – 15 Excellent 
12 – 16 Good 
18 – 21 Fair to Passable 
2 – 35 Poor 
33 – 38 Very Poor 
>40 Very Very Poor 
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Formulation development of Tablets: 
Molsidomine colon targeted tablets were prepared by using 
compression coating technology. Initially internal core tablet 
containing drug and super disintegrate was formulated. For 
the prepared core tablet compression coating is done by 
using various compositions of polymers. Ethyl cellulose, 
Polymethacrylate polymers such as Eudragit L100 and 
Eudragit S100 are used as polymers for compression 
coating. 
Tablets are developed in two stages 
1) Preparation of core tablet containing drug and super 
disintegrate. 
2) Compression coating of prepared core tablets. 
Formulation of core tablet: 
The core tablets are formulated by using 250 mg of drug 
molecule, sodium starch glycollate as super disintegrate, 
Micro crystalline cellulose as iluents, talc and magnesium 
stearate as Glidant and Lubricant respectively. The 
composition of core tablet was given in below table. 
Table 3: Composition of core tablet 
Ingredient Name Quantity (mg) 
Molsidomine 8 
Sodium starch glycollate 30 
Talc 5 
Magnesium stearate 5 
MCC pH102 52 
Total weight 100 
 
Total weight of core tablet was fixed as 100 mg. The tablets 
are prepared by using 6mm flat punch. Then the prepared 
core tablets are subjected to compression coating by using 
various compositions of polymers. 
Formulation of compression coated tablets: 
The prepared core tablets were subjected to compression 
coating by using various compositions of polymers such as 
Ethyl cellulose, Eudragit L 100 and Eudragit S 100 as coating 




Table 4: Composition of coating layer 
Ingredient name F1 F2 F3 F4 F5 F6 F7 F8 F9 
Ethyl cellulose (mg) 50 100 - - - - 50 - 50 
Eudragit S100 (mg) - - 50 100 - - 50 50 - 
Eudragit L100 (mg) - - - - 50 100 - 50 50 
Magnesium stearate (mg) 3 3 3 3 3 3 3 3 3 
Talc (mg) 3 3 3 3 3 3 3 3 3 
MCC pH 102 (mg) 144 94 144 94 144 94 94 94 94 
Total weight 200 200 200 200 200 200 200 200 200 
 
 
Compression coating layer was divided into two equal 
portions i.e., 50mg of each quantity .Half of the quantity of 
powder blend was placed in the die cavity, core tablet was 
placed exactly in the middle of die cavity and then remaining 
quantity of powder blend was placed over the core tablet so 
that the powder blend should cover all the sides and top side 
of core tablet uniformly. Then the tablets are compressed by 
using 9mm flat surfaced punch using 8 station tablet 
punching machine with the hardness of 4-4.5 kg/cm
2
.Then 
the prepared compression coted tablets are evaluated for 
various post compression parameters as per standard 
specifications. 
Evaluation of post compression parameters for 
prepared Tablets 
The designed formulation compression coated tablets were 
studied for their physicochemical properties like weight 
variation, hardness, thickness, friability and drug content. 
Weight variation test: 
To study the weight variation, twenty tablets were taken and 
their weight was determined individually and collectively on 
a digital weighing balance. The average weight of one tablet 
was determined from the collective weight. The weight 
variation test would be a satisfactory method of deter mining 
the drug content uniformity. Not more than two of the 
individual weights deviate from the average weight by more 
than the percentage shown in the following table and none 
deviate by more than twice the percentage. The mean and 
deviation were determined. The percent deviation was 
calculated using the following formula. 
% Deviation =  
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Table 5: Pharmacopoeial specifications for tablet weight variation 
Average weight of tablet  
(mg) (I.P) 
Average weight of tablet  
(mg) (U.S.P) 
Maximum percentage  
difference allowed 
Less than 80 Less than 130 10 
80-250 130-324 7.5 




Hardness of tablet is defined as the force applied across the 
diameter of the tablet in order to break the tablet. The 
resistance of the tablet to chipping, abrasion or breakage 
under condition of storage transformation and handling 
before usage depends on its hardness. For each formulation, 
the hardness of three tablets was determined using 
Monsanto hardness tester and the average is calculated and 
presented with deviation21,22. 
Thickness: 
Tablet thickness is an important characteristic in 
reproducing appearance. Tablet thickness is an important 
characteristic in reproducing appearance. Average thickness 
for core and coated tablets is calculated and presented with 
deviation. 
Friability: 
It is measured of mechanical strength of tablets. Roche 
friabilator was used to determine the friability by following 
procedure. Preweighed tablets were placed in the friabilator. 
The tablets were rotated at 25 rpm for 4 minutes (100 
rotations). At the end of test, the tablets were re weighed, 
loss in the weight of tablet is the measure of friability and is 
expressed in percentage as 
% Friability = [(W1-W2) / W] × 100 
Where,   W1 = Initial weight of three tablets 
W2 = Weight of the three tablets after testing 
Determination of drug content: 
Both compression-coated tablets of were tested for their 
drug content. Ten tablets were finely powdered quantities of 
the powder equivalent to one tablet weight of Molsidomine 
were accurately weighed, transferred to a 100 ml volumetric 
flask containing 50 ml water and were allowed to stand to 
ensure complete solubility of the drug. The mixture was 
made up to volume with water. The solution was suitably 
diluted and the absorption was determined by UV –Visible 
spectrophotometer. The drug concentration was calculated 
from the calibration curve. 
In-vitro drug release studies 
Drug release studies of Molsidomine core tablets: 
The core tablets containing 15mg of Molsidomine were 
tested in (pH 6.8), for their dissolution rates. Dissolution 
studies were performed using USP paddle type sample of 5 
ml was withdrawn and replaced with equal volume of fresh 
medium. The samples were analyzed spectrophotometrically 
at respective 270 nm. 
Drug release studies of Compression coated 
Molsidomine tablets: 
The release of Molsidomine from coated tablets was carried 
out using USP paddle-type dissolution apparatus at a 
rotation speed of 50 rpm, and a temperature of 37±0.5 °C. 
For tablets, simulation of gastrointestinal transit conditions 
was achieved by using different dissolution media. Thus, drug 
release studies were conducted in simulated gastric fluid 
(SGF, pH 1.2) for the first 2 hours as the average gastric 
emptying time is about 2 hours. Then, the dissolution 
medium was replaced with enzyme- free simulated intestinal 
fluid ( SIF, pH 7.4 ) and tested for drug release for 3 hours, as 
the average small intestinal transit time is about 3 hours, and 
finally enzyme- free simulated intestinal fluid ( SIF, pH 6.8 ) 
was used upto 12 hours to mimic colonic pH conditions. 
Drug release was measured from compression coated 
Molsidomine tablets, added to 900 ml of dissolution medium. 
5 ml of sample was withdrawn every time and replaced with 
fresh medium,  samples withdrawn at various time intervals 
were analyzed spectrophotometrically at 275 nm and 270 
nm respectively. All dissolution runs were performed for six 
batches. The results were given with deviation. 
Application of release rate kinetics to dissolution data: 
Various models were tested for explaining the kinetics of 
drug release. To analyze the mechanism of the drug release 
rate kinetics of the dosage form, the obtained data were 
fitted into zero-order, first order, Higuchi, and Korsmeyer-
Peppas release model. 
Zero order release rate kinetics: 
To study the zero–order release kinetics the release rate 
data are fitted to the 
following equation. 
F = Ko t 
Where, ‘F’ is the drug release at time‘t’, and ‘Ko’ is the zero 
order release rate constant. The plot of % drug release versus 
time is linear. 
First order release rate kinetics: The release rate data are 
fitted to the following equation 
Log (100-F) = kt 
A plot of log cumulative percent of drug remaining to be 
released vs. time is plotted then it gives first order release. 
Higuchi release model: To study the Higuchi release 
kinetics, the release rate data were fitted to the following 
equation. 
F = k t1/2 
Where, ‘k’ is the Higuchi constant. 
In higuchi model, a plot of % drug release versus square root 
of time is linear. 
Korsmeyer and Peppas release model: 
The mechanism of drug release was evaluated by plotting the 
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log percentage of drug released versus log time according to 
Korsmeyer- Peppas equation. The exponent ‘n’ indicates the 
mechanism of drug release calculated through the slope of 
the straight Line. 
Mt/ M∞  = K tn 
Where, Mt/ M∞ is fraction of drug released at time ‘t’, k 
represents a constant, and ‘n’ is the diffusional exponent, 
which characterizes the type of release mechanism during 
the dissolution process. For non-Fickian release, the value of 
n falls between 0.5 and 1.0; while in case of Fickian diffusion, 
n = 0.5; for zero-order release (case I I transport), n=1; and 
for supercase II transport, n > 1. In this model, a plot of log 
(Mt/ M∞) versus log (time) is linear. 
Hixson-Crowell release model: 
 
(100-Qt) 1/3 = 1001/3– KHC.t 
Where, k is the Hixson-Crowell rate constant. 
Hixson-Crowell model describes the release of drugs from an 
insoluble matrix through mainly erosion. (Where there is a 
change in surface area and diameter of particles or tablets). 
Stability Studies: 
Optimized formulation was subjected to stability studies for 
three months at 40ºC  with 75±5% RH as per ICH guidelines. 
The tablets were analysed for Hardness, In- vitro 
disintegration time, drug content and cumulative % drug 
released till a period of 3 months.  
RESULTS AND DISCUSSION 
The present study was aimed to develop compression coated 
Molsidomine formulations for colon targeting using ethyl 
cellulose and enteric coating polymers like Eudragit L 100 
and Eudragit S 100. All the formulations were evaluated for 
physicochemical properties and in-vitro drug release studies. 
Analytical Method 
Graphs of Molsidomine was taken in Simulated Gastric fluid 
(pH 1.2) and Simulated Intestinal Fluid (pH 6.8 and 7.4) 
 
 
Fig 1: Standard graph of Molsidomine in 0.1N HCl 
 
 
Fig 2: Standard graph of Molsidomine in 6.8 pH 
 
 
Fig 3: Standard graph of Molsidomine in 7.4 pH
 
 
Drug and excipient compatibility studies: 
 
Fig 4: FT-IR spectrum of pure drug 
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Fig 5: FT-IR spectrum of optimised formulation 
 
Pre-formulation parameters 
Table 6. Pre-formulation parameters of core material 
Formulation  
Code 







F1 36.01± 0.11 0.55± 0.14 0.645± 0.24 14.72± 0.14 0.85± 0.19 
F2 34.8± 0.18 0.57± 0.12 0.66± 0.22 13.63± 0.23 0.86± 0.24 
F3 32.74± 0.17 0.53± 0.23 0.606± 0.27 14.19± 0.31 0.858± 0.17 
F4 35.33± 0.22 0.531± 0.16 0.613± 0.29 13.37± 0.14 0.866± 0.26 
F5 36.24± 0.13 0.549± 0.28 0.641± 0.18 14.35± 0.26 0.856± 0.31 
F6 36.12± 0.24 0.564± 0.39 0.666± 0.19 15.31± 0.24 0.846± 0.24 
F7 37.08± 0.6 0.581± 0.17 0.671± 0.12 13.41± 0.29 0.865± 0.29 
F8 35.12± 0.15 0.567± 0.25 0.654± 0.13 13.12± 0.17 0.845± 0.11 
F9 35.45± 0.25 0.571± 0.12 0.689± 0.15 13.28± 0.18 0.855± 0.18 
 
 
Molsidomine blend was subjected to various pre-formulation 
parameters. The apparent bulk density and tapped bulk 
density values ranged from 0.52 to 0.581 and 0.606 to 0.671 
respectively. According to tables, the results of angle of 
repose and compressibility index (%) ranged from 
32.74±0.12 to 37.08±0.96 and 13.37±0.38 to 14.72±0.62 
respectively. The results of angle of repose (<35) and 
compressibility index (<23) indicates fair to passable flow 
properties of the powder mixture. These results show that 
the powder mixture has good flow properties. The 
formulation blend was directly compressed to tablets and in-
vitro drug release studies were performed. 
Quality Control Parameters for compression coated 
tablets: 
Tablet quality control tests such as weight variation, 
hardness, and friability, thickness, and drug release studies 
in different media  were performed on the compression 
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Drug content (%) 
F1 312.5± 0.24 4.5± 0.24 0.52± 0.14 4.8± 0.11 99.76± 0.19 
F2 305.4± 0.11 4.2± 0.41 0.54± 0.24 4.9± 0.19 99.45± 0.24 
F3 298.6± 0.18 4.4± 0.11 0.51± 0.32 4.9± 0.32 99.34± 0.18 
F4 310.6± 0.21 4.5± 0.18 0.55± 0.19 4.9± 0.22 99.87± 0.36 
F5 309.4± 0.32 4.4± 0.39 0.56± 0.29 4.7± 0.18 99.14± 0.17 
F6 310.7± 0.17 4.2± 0.19 0.45± 0.11 4.5± 0.31 98.56± 0.29 
F7 302.3± 0.41 4.1± 0.23 0.51± 0.27 4.4± 0.29 98.42± 0.15 
F8 301.2± 0.38 4.3± 0.31 0.49± 0.18 4.7± 0.21 99.65± 0.41 
F9 298.3± 0.31 4.5± 0.43 0.55± 0.19 4.6± 0.22 99.12± 0.11 
All the parameters such as weight variation, friability, hardness, thickness and drug content were found to be within limits. 
 
In-Vitro Drug Release Studies 
The compression coated tablets containing 250mg of 
Molsidomine were tested in 6.8 pH phosphate buffer 
solution for their dissolution rates. The release of 
Molsidomine from compression coated tablets was carried 
out using USP paddle-type dissolution apparatus at a 
rotation speed of 50 rpm, and a temperature of 37±0.5 °C. 
For tablets, simulation of gastrointestinal transit conditions 
was achieved by using different dissolution media. Thus, 
drug release studies were conducted in simulated gastric 
fluid (SGF, pH 1.2) for the first 2 hours as the average gastric 
emptying time is about 2 hours. Then, the dissolution 
medium was replaced with enzyme- free simulated 
intestinal fluid ( SIF, pH 7.4 ) and tested for drug release for 
3 hours, as the average small intestinal transit time is about 
3 hours, and finally enzyme- free simulated intestinal fluid ( 
SIF, pH 6.8 ) was used upto 12 hours to mimic colonic pH 
conditions. 
Drug release was measured from compression coated 
Molsidomine tablets, added to 900 ml of dissolution medium. 
5 ml of sample was withdrawn every time and replaced with 
fresh medium,  samples withdrawn at various time intervals 
were analyzed spectrophoto metrically at 275 nm, 319 and 




Table 8: In-vitro drug release profile for coated formulations (F1-F9) 
Time          
(hrs) 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
1 5.42 0.26 0.34 2.39 1.11 1.44 8.06 2.65 1.32 
2 12.65 0.44 0.54 17.88 1.29 12.30 20.94 7.23 2.14 
3 23.56 4.65 1.26 30.45 11.71 24.44 30.26 18.19 2.90 
4 66.8 17.87 2.22 40.59 30.22 36.61 45.44 30.27 8.11 
5 86.9 29.18 3.05 55.01 40.18 47.30 63.86 42.06 17.72 
6 98.35 35.45 18.41 73.85 54.53 55.68 72.93 51.40 30.40 
7 99.76 61.04 30.05 91.92 63.88 67.53 90.23 69.13 51.64 
8 -- 74.24 48.69 96.11 80.53 78.72 97.32 78.45 61.59 
9 -- 88.13 55.38 -- 95.06 83.34 -- 85.67 74.97 
10 -- 96.39 72.34 -- 95.18 90.67 -- 98.45 84.18 
11 -- -- 87.56 -- -- 98.12 -- 98.12 91.87 
12 -- -- 97.57 -- -- -- -- -- 95.45 
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From the dissolution values it was evident that the 
formulations F3 & F9 were retarded the drug release up to 
12 hours, they shown drug release of 97.57 and 95.45 %   
respectively.   Formulations   F1–F3   contains   ethyl    
cellulose   alone.   As   the concentration of ethyl cellulose 
increases retardation nature was increased. F3 formulation 
containing 150 mg of ethyl cellulose was show almost 
negligible amount of drug release in first 3 hours from the 5 
th hour onwards it shown drug release as the time proceeds 
slowly the polymer was undergone erosion and allowed the 
drug to come out from the dosage form. The formulation was 
retarded drug release up to 12 hours and it showed 
maximum drug release in 12 hours i,e., in colon region. 
Similarly the formulation F9 containing Eudragit L 100 in the 




Fig 6: Comparison of In-vitro dissolution profile of CORVATON (Marketed product) with Optimized formulation (F3) 
 
Fig 7: Zero order release kinetics graph 
 
Fig 8: Higuchi release kinetics graph 
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Fig 9: Korsmeyer peppas graph 
 
Fig 10: First order release kinetics graph 
 
From the above graphs it was evident that the formulation 
F3 followed zero order kinetics. 
Stability Studies: 
Optimized formulation was subjected to stability studies for 
three months at 40ºC  with 75±5% RH as per ICH guidelines. 
The tablets were analysed for hardness, in-vitro 
disintegration time, drug content and cumulative % drug 
released till a period of 3 months.  
 
Table 9: Stability studies of optimized formulation F3 (Three months at 40ºC with 75±5% RH) 
Parameters Initial At the end of 1st 
month 
At the end of 2nd 
month 
At the end of 3rd 
month 
Hardness (Kg/cm2) 4.51±0.19 4.49±0.10 4.53±0.17 4.47±0.11 
Wetting time (sec) 32.63±0.26 32.55±0.23 32.45±0.25 32.42±0.21 
Drug content (%) 99.31±0.24 99.25±0.21 99.29±0.29 99.21±0.24 
Cumulative percent  
drug release 
97.57±0.18 97.65±0.15 97.51±0.12 97.45±0.20 
 
CONCLUSION 
In the present research work sustained release matrix 
formulation of Molsidomine targeted to colon by using 
various polymers was developed. FT-IR studies revealed that 
there was no interaction between the selected drug and 
excipients. The pre-compression blend of all formulations 
was subjected to various flow property tests and all the 
formulations passed the tests. The tablets were coated by 
using polymers and the coated tablets were subjected to 
various evaluation techniques. The tablets passed all the 
tests. Among all the formulations F3 formulation was found 
to be optimized as it was retarded the drug release up to 12 
hours and showed maximum of 97.57% drug release. It 
followed zero order kinetics mechanism. The ideal 
formulation was subjected to stability studies at 
40°C/75%RH. The stability studies indicated that the 
formulation was stable and retained its pharmaceutical 
properties at 40°C/75%RH over a period of 1 month.  
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